• 23 Sep 2019

Morning Note – 23 September 2019

Iofina, 24.8 | Omega Diagnostics Group, 11.5 | Destiny Pharma, 41.5 | Evgen Pharma, 7.4

    • Mark Brewer

    • 7 pages

Stock Image


 
Stock Image


Destiny Pharma (DEST): Corp Interims – extended cash runway into 2021 | Evgen Pharma (EVG): Corp Positive update from breast cancer STEM trial | Iofina (IOF): Corp Record results a taster of what’s to come |Omega Diagnostics (ODX): Corp Full-year results – VISITECT visibility


Sign up to access

Get access to our full offering from over 30 providers

Get access to our full offering from over 30 providers


Get Started
Already a member? Log in here

More Content

More Content

Destiny Pharma - Eyes on the Phase IIb prize

Companies: Destiny Pharma

Iofina PLC's Tom Becker updates on Organic Vines investment and IO#8 construction

Companies: Iofina

SP Angel Healthcare Conditions

Companies: Evgen Pharma Microsaic Systems

Iofina PLC's Tom Becker hails record first-half profits as production expands

Companies: Iofina

Morning Note – 5 December 2019

Companies: Evgen Pharma Circassia Pharmaceuticals

Copyright © 2019 Research Tree | All Rights Reserved. | Terms of Service and Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Tools licensed and contents implemented and optimized by Digital Look Ltd.

DigitalLook |Web Financial Group

©1999-2013 – Digital Look Ltd. A Web Financial Group Company All rights reserved. Legal notice.

Top